http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Intelligent Bio Solutions Announces Fiscal Q2 2025 Financial Results and Key Operational Achievements
-
Intelligent Bio Solutions Releases Shareholder Letter Detailing 2024 Growth and 2025 U.S. Expansion Strategy
-
Intelligent Bio Solutions (INBS) Expands with UK Partnership
-
Intelligent Bio Solutions Expands with UK Partnership, Driving Global Growth Ahead of Planned U.S. Launch
-
Intelligent Bio Solutions expects to achieve 32.6% Gross Profit Expansion and Increased Profitability on Higher-Margin Sales
-
Intelligent Bio Solutions (INBS) Expands Global Reach with Multilingual Drug Screening System Upgrade
-
Intelligent Bio Solutions Expands Global Reach with Multilingual Drug Screening System Upgrade
-
Global Drug Screening Market Is Forecasted to Reach $19.5 Billion By 2029
-
Intelligent Bio Solutions (INBS) Adds Quantum TM to 400+ Account Portfolio Utilizing Breakthrough Fingerprint Drug Testing
-
Intelligent Bio Solutions Adds Quantum TM to 400+ Account Portfolio Utilizing Breakthrough Fingerprint Drug Testing
-
Intelligent Bio Solutions Partners with IVY Diagnostics to Expand in Europe’s $3.6 Billion Drug Screening Market and in Middle Eastern Regions
-
Intelligent Bio Solutions Partners with Princebuild to Transition from Saliva Testing to Fingerprint Sweat-Based Drug Screening Across its Seven UK Sites
-
Intelligent Bio Solutions (INBS) Announces 510(k) Submission to US FDA for Fingerprint Sweat-Based Drug Screening Technology
-
Intelligent Bio Solutions Announces 510(k) Submission to US FDA for Fingerprint Sweat-Based Drug Screening Technology
-
Intelligent Bio Solutions (INBS) Achieves 94.1% Accuracy in Method Comparison Study
-
Intelligent Bio Solutions Achieves 94.1% Accuracy in Method Comparison Study, Following Positive PK Study Results
-
Intelligent Bio Solutions (INBS) Announces Positive Results of PK Study, a Key Milestone on Path to FDA 510(k) Submission
-
Intelligent Bio Solutions Announces Positive Results of PK Study, a Key Milestone on Path to FDA 510(k) Submission
-
Intelligent Bio Solutions Reports Fiscal 2025 First Quarter Financial Results and Operational Highlights
-
Intelligent Bio Solutions (INBS) Partners with B2i Digital to Amplify Investor Outreach
-
Intelligent Bio Solutions Partners with B2i Digital to Amplify Investor Outreach
-
Intelligent Bio Solutions (INBS) Reports Prelim Q1 Results
-
Intelligent Bio Solutions Announces Preliminary Unaudited Fiscal 2025 First Quarter Revenue Results
-
Intelligent Bio Solutions Celebrates One Year Anniversary of Enhanced Workplace Safety with London-Based Real-Estate Developer, Mount Anvil
-
Intelligent Bio Solutions (INBS) Announces Adoption of its Non-Invasive Drug Screening Solution by Global Engineering Leader, Pyrotek
-
Intelligent Bio Solutions Announces Adoption of its Non-Invasive Drug Screening Solution by Global Engineering Leader, Pyrotek
-
GPS Marine Adopts Intelligent Bio Solutions’ Fingerprint Drug Testing Technology to Boost Workplace Safety in Maritime Services
-
Intelligent Bio Solutions (INBS) Concludes In-Clinic Testing for Clinical Study Plan, Advancing Toward FDA 510(k) Submission
-
Intelligent Bio Solutions Concludes In-Clinic Testing for Clinical Study Plan, Advancing Toward FDA 510(k) Submission
-
Intelligent Bio Solutions to Participate in the Sidoti Small-Cap Virtual Conference on September 18-19, 2024
-
Intelligent Bio Solutions Inc. Reports 118% Year-Over-Year Growth in Customer Employee Base, Reaching an Estimated Total of 1.4 Million Employees
-
Intelligent Bio Solutions (INBS) Achieves Major Milestone with Over 1,000 Installed Intelligent Fingerprinting Drug Screening Readers as of June 30, 2024
-
Intelligent Bio Solutions Inc. Achieves Major Milestone with Over 1,000 Installed Intelligent Fingerprinting Drug Screening Readers as of June 30, 2024
-
Intelligent Bio Solutions Inc. Highlights Growing Need for Drug Testing Solutions in Key Industries
-
Intelligent Bio Solutions Partners with CenExel to Conduct Clinical Study as Part of FDA 510(k) Pathway
-
Intelligent Bio Solutions Inc. Announces QabasTech as Exclusive Distributor in Saudi Arabia
-
Intelligent Bio Solutions (INBS) Advances on FDA 510(k) Pathway with Biocompatibility Study Success
-
Intelligent Bio Solutions Inc. Advances on FDA 510(k) Pathway with Biocompatibility Study Success
-
Intelligent Bio Solutions Strengthens UK Market Position with Addition of Key Manufacturing Accounts
-
Intelligent Bio Solutions Completes In-Clinic Portion of Pharmacokinetic (PK) Study Part of 510(k) Pathway for Approval & Commences Review of Results
-
Intelligent Bio Solutions Completes In-Clinic Portion of Pharmacokinetic (PK) Study Part of 510(k) Pathway for Approval & Commences Review of Results
-
Intelligent Bio Solutions (INBS) Expands Presence in the UK Retail Sector with Major Account Acquisitions
-
Intelligent Bio Solutions Expands Presence in the UK Retail Sector with Major Account Acquisitions
-
Intelligent Bio Solutions Broadens UK Customer Base by Securing Two Key Accounts with Over 70 Locations and Over 15,000 Employees in the Warehouse and Logistics Sector
-
Intelligent Bio Solutions Begins Subject Dosing and Sampling for FDA 510(k) Pharmacokinetic (PK) Study for its Intelligent Fingerprinting Drug Screening Technology
-
Intelligent Bio Solutions Implements Strategic Reorganization Plan to Support Global Growth Initiatives
-
Intelligent Bio Solutions (INBS) Adds Major European Transport and Infrastructure Solutions Provider to Growing Number of Accounts Adopting Fingerprint Drug Screening Technology
-
Intelligent Bio Solutions Adds Major European Transport and Infrastructure Solutions Provider to Growing Number of Accounts Adopting Fingerprint Drug Screening Technology
-
Intelligent Bio Solutions to Participate in the Sidoti Small-Cap Conference on June 12-13, 2024
-
Intelligent Bio Solutions Successfully Completes Recruitment and Begins Subject Screening for FDA 510(k) Pharmacokinetic (PK) Study

